ESC
One QuanticSphere™ PQNS platform, two 250 mg SKUs: clean-label or peak-exposure, delivering sustained plasma curcuminoid levels for 14–20 hours.
Peak exposure or clean label — both built on the same QuanticSphere™ PQNS platform, 250 mg per dose.
Plasma curcuminoids after a single dose: Q-Curviva and Q-Curviva Lite (250 mg) vs raw curcumin (1,000 mg).
| Parameter | Raw1,000 mg | Lite250 mg | Q-Curviva250 mg |
|---|---|---|---|
| Plasma ≥ 50 ng/mL | 0 h (never) | ~14.6 h | ~20.6 h |
| Plasma half-life (t½) | 2.9 h | 7.2 h | 7.2 h |
| Plasma at 12 h | ~baseline | ~60 ng/mL | ~100 ng/mL |
| Cmax | 30 ng/mL | 141 ng/mL | 234 ng/mL |
| AUC₀–₇₂₀ (ng·h/mL) | 254 | 1,570 | 5,125 |
| Bioavailability vs raw | 1× | 24.7× | 80.6× |
Read it on duration. Raw curcumin at 1,000 mg never crosses 50 ng/mL (peak just 30). Q-Curviva at 12 h (~100 ng/mL) is still about 3× raw’s peak — from a quarter of the dose.
Curcumin support: a central area of curcumin research.
Cellular defense: curcumin is studied for its antioxidant role.
Everyday ease: joint comfort and mobility are active curcumin research areas.
A single daily dose supports adherence.
These concepts draw on curcumin research, not established Q-Curviva health benefits. Product-specific substantiation is required.
Increasing the amount of curcumin alone may not resolve its delivery limitations. Q-CURVIVA is built around the particle itself, giving brands an ingredient proposition grounded in engineered delivery.
Charged phospholipid nanoencapsulation for phytochemicals. A cationic surface adheres to the intestinal mucosa, converts crystalline curcumin into a fast-dissolving amorphous state, and shields it from gastric acid, oxidation and first-pass metabolism.
Market figures are category context from third-party analysts, not a head-to-head or efficacy claim.
Q-Curviva is engineered around the plasma profile, not just the peak. One QuanticSphere™ PQNS platform, two 250 mg SKUs, delivers 24.7×–80.6× the bioavailability of raw curcumin and sustained plasma curcuminoid levels for 14–20 hours.
Q-Curviva (flagship, with 25 mg piperine) is the peak-exposure option: 80.6× bioavailability vs raw, about 20.6 h at ≥50 ng/mL, Cmax 234 ng/mL, AUC 5,125. Q-Curviva Lite is the clean-label, piperine-free option with no bioenhancer: 24.7× bioavailability vs raw, about 14.6 h at ≥50 ng/mL, Cmax 141 ng/mL, AUC 1,570. Both are 250 mg.
About 20.6 hours for Q-Curviva and about 14.6 hours for Q-Curviva Lite. Raw curcumin at 1,000 mg never reaches 50 ng/mL (Cmax 30 ng/mL). Plasma half-life is 7.2 h for both Q-Curviva SKUs vs 2.9 h for raw curcumin. Illustrative reconstruction from the supplied single-dose chart.
QuanticSphere™ PQNS is a Phytosome Quantum Nano Sphere: charged phospholipid nanoencapsulation whose cationic surface adheres to the intestinal mucosa. It converts crystalline curcumin into a fast-dissolving amorphous state and shields it from gastric acid, oxidation and first-pass metabolism. Particle size 114.6 nm (DLS), PDI 0.273 (monodisperse), zeta potential +43.0 mV.
Healthy inflammatory response (curcumin support), antioxidant support (cellular defense), joint & mobility comfort (everyday ease), and once-daily dosing that supports adherence. These concepts draw on curcumin research, not established Q-Curviva health claims — product-specific substantiation is required.
Facility: NSF/ANSI 455-2 certified GMP, FSSC 22000, ISO 9001/14001/45001. Regulatory: 21 CFR Part 111, Halal Certified. Dissolution: approximately 95–100% release, batch-consistent. IP: QuanticSphere™ PQNS, patent pending 202521095813.
Share your formulation requirements and our team can walk you through the full Q-Curviva clinical dossier, supply format and technical specifications.
Talk to a Specialist